• info@arocell.com
  • +46 (0)18 50 30 20
  • English
  • Svenska
Arocell TK 210 ELISA kit
  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
    • Press releases
    • Meet AroCell
  • investors
    • AroCell – Company overview
    • The share
    • Financial report
    • Share issues
    • Press releases
    • Financial presentations
    • Financial calendar
    • Annual General Meeting
    • Governance
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Order
    • Q & A
Menu
  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
      • Hematological malignancies
      • Breast cancer
      • Other solid tumors
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Press releases
    • Meet AroCell
  • investors
    • AroCell – Company overview
    • The share
      • Ownership structure
    • Financial report
    • Share issues
      • Nyemission 2018
      • Listing at First North 2016
      • Nyemission 2015
    • Press releases
    • Financial presentations
    • Financial calendar
    • Annual General Meeting
      • Annual General Meeting 2018
      • Annual general meeting 2017
      • Annual general meeting 2016
      • Annual general meeting 2015
    • Governance
      • Board of Directors
      • Management
      • Articles of association
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Order
    • Q & A
  • AroCell – Company overview
  • The share
    • Ownership structure
  • Financial report
  • Share issues
    • Nyemission 2018
    • Listing at First North 2016
    • Nyemission 2015
  • Press releases
  • Financial presentations
  • Financial calendar
  • Annual General Meeting
    • Annual General Meeting 2018
    • Annual general meeting 2017
    • Annual general meeting 2016
    • Annual general meeting 2015
  • Governance
    • Board of Directors
    • Management
    • Articles of association
  • Certified advisor
  • Investor relations contact

Financial calendar

2019-02-21 Year end report 2018
2019-05-16 Interim report 1, 2019
2019-05-16 Annual general meeting 2019
2019-08-21 Interim report 2, 2019
2019-11-15 Interim report 3, 2019

 

Subscription for news and press releases

  • about
    • A word from the CEO
    • Vision and mission
    • Strategy and goals
    • Board of Directors
    • Management
    • Company history
    • Policies
  • product
    • AroCell TK 210 ELISA
    • Why measure Thymidine Kinase 1?
    • Performance and technical specifications
    • Instructions for use
  • applications
    • Drug discovery and development
    • Clinical cancer research
      • Hematological malignancies
      • Breast cancer
      • Other solid tumors
    • Clinical studies
    • Scientific references
    • Posters and presentations
  • technologies
    • Thymidine Kinase 1
    • Patent portfolio
    • Scientific references
    • Posters and presentations
  • news & media
    • News
    • Press releases
    • Meet AroCell
  • investors
    • AroCell – Company overview
    • The share
      • Ownership structure
    • Financial report
    • Share issues
      • Nyemission 2018
      • Listing at First North 2016
      • Nyemission 2015
    • Press releases
    • Financial presentations
    • Financial calendar
    • Annual General Meeting
      • Annual General Meeting 2018
      • Annual general meeting 2017
      • Annual general meeting 2016
      • Annual general meeting 2015
    • Governance
      • Board of Directors
      • Management
      • Articles of association
    • Certified advisor
    • Investor relations contact
  • contact & order
    • Contact
    • Distributors
    • Order
    • Q & A
  • English
  • Svenska
AroCell AB Uppsala Business Park
Virdings allé 32 B
SE-754 50 Uppsala Sweden
  • info@arocell.com
  • +46 (0)18 50 30 20

POLICIES

All of the information appearing on this website is not intended to be used for medical diagnosis or treatment. Information provided on this website does not either constitute medical and/or other professional advice. AroCell TK 210 ELISA is CE-marked and registered by the Swedish Medical Products Agency.

We use cookies to improve the user experience and gather anonymous visitor statistics. By using our website, you agree to the use of cookies.

I agree.